news
Scientists unveil first molecular-level analysis of Omicron spike protein
Using cryo-electron microscopy, researchers have completed the world’s first molecular analysis of the SARS-CoV-2 Omicron spike protein.
List view / Grid view
Covid-19
news
Memory T cells respond to SARS-CoV-2 Omicron variant, study shows
Research has shown that memory T cells formed following SARS-CoV-2 infection or mRNA vaccination respond to the Omicron variant.
article
CRISPR activation screening: finding genes that interact with SARS-CoV-2
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
news
Sino Biological deposits recombinant Omicron proteins and antibodies to BEI Resources
To support disease research, Sino Biological has deposited reagents for the Omicron variant to BEI Resources.
news
Collaborative research efforts enabled rapid response to Omicron variant
News from the Pasteur Institute in France reports on how multi organisational efforts of numerous research institutes enabled the scientific community to gain key insight into the Omicron variant, facilitating a rapid life-saving response.
news
Nanoparticle delivery of CRISPR enables genome editing of vascular endothelium
According to researchers, a new method to deliver CRISPR-Cas9 to vascular endothelial cells could be used to treat many diseases, including COVID-19.
news
Antibodies that can neutralise SARS-CoV-2 Omicron variant identified
A study has revealed four classes of antibodies that can neutralise Omicron by targeting one of four areas of the spike protein present in SARS-CoV-2 variants.
article
Thriving biotech: three stocks building momentum
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
news
Sino Biological launches panel of research reagents for SARS-CoV-2 Omicron variant (B.1.1.529)
Sino Biological, Inc. has just launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world due to the high number of mutations it carries, particularly the 30-plus mutations on the Spike protein.
news
New platform screens for specific class of coronavirus antiviral compounds
Researchers developed a platform that can rapidly screen thousands of compounds to identify potential antiviral drugs to treat coronaviruses.
article
Nanobodies that bind a component of the SARS-CoV-2 replication complex
Professors Piergiorgio Percipalle and Gennaro Esposito summarise their study which revealed two nanobodies that could inhibit a non-structural protein of SARS-CoV-2.
article
mRNA vaccine technology – a promising platform for novel vaccine development
Dr Pushpanathan Muthuirulan explores why messenger RNA (mRNA) is advantageous for vaccine development and how the COVID-19 pandemic has accelerated its progress within the pharmaceutical industry.
news
Key mechanism reveals how SARS-CoV-2 evades our immune system
Scientists have found that SARS-CoV-2 can knock out an important molecular pathway linked to an immune complex called MHC class I.
news
Researchers delineate novel COVID-19 subgroups in critically ill patients
The new study used sequence clustering analysis to identify four subgroups of COVID-19 to help match patients to specific treatments.
news
“Overlooked” FAM72A gene shines light on antibody production
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.